Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid (Q36303956)

13 August 2017

1 reference

title

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid (English)

1 reference

13 August 2017

William Kevin Kelly

1

1 reference

13 August 2017

Paul A Marks

series ordinal

2

1 reference

13 August 2017

publication date

1 March 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

150-157

1 reference

Histone Deacetylase Inhibitors

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

The Discovery of NVP-LAQ824: From Concept to Clinic

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Deviant nucleosomes: the functional specialization of chromatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Crystal structure of the nucleosome core particle at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

An increasingly complex code

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Binary switches and modification cassettes in histone biology and beyond.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylases, transcriptional control, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylases (HDACs): characterization of the classical HDAC family

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

The fundamental role of epigenetic events in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

The diversity of acetylated proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Acetylation: a regulatory modification to rival phosphorylation?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0106

7 January 2021

Identifiers

DOI

10.1038/NCPONC0106

1 reference

13 August 2017

1 reference